Type 1 and Type 2 cytokines imbalance in adult male C57BL/6 mice following a 7-day oral exposure to perfluorooctanesulfonate (PFOS)

References

• Alexander, B. H., Olsen, G. W., Burris, J. M., Mandel, J. H. and Mandel, J. S. 2003. Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup. Environ. Med. 60:722–729.
   PubMed Web of Science ®Google Scholar
• Austin, M. E., Kasturi, B. S., Barber, M., Kannan, K., MohanKumar, P. S. and MohanKumar, S. M. 2003. Neuroendocrine effects of perfluorooctane sulfonate in rats. Environ. Health Perspect. 111:1485–1489.
   PubMed Web of Science ®Google Scholar
• Berghella, A. M., Contasta, I., Pellegrini, P., Del Beato, T. and Adorno, D. 2006. Are immunological mechanisms involved in colon cancer and are they possible markers for biotherapy improvement? Cancer Biother. Radiopharm. 21:468–487.
   PubMedGoogle Scholar
• Bermejo-Martin, J. F., Ortiz de Lejarazu, R., Pumarola, T., Rello, J., Almansa, R., Ramírez, P., Martin-Loeches, I., Varillas, D., Gallegos, M. C., Serón, C., Micheloud, D., Gomez, J. M., Tenorio-Abreu, A., Ramos, M. J., Molina, M. L., Huidobro, S., Sanchez, E., Gordón, M., Fernández, V., Del Castillo, A., Marcos, M. A., Villanueva, B., López, C. J., Rodríguez-Domínguez, M., Galan, J. C., Cantón, R., Lietor, A., Rojo, S., Eiros, J. M., Hinojosa, C., Gonzalez, I., Torner, N., Banner, D., Leon, A., Cuesta, P., Rowe, T. and Kelvin, D. J. 2009. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit. Care. 13:R201.
   Web of Science ®Google Scholar
• Boonstra, A., Rajsbaum, R., Holman, M., Marques, R., Asselin-Paturel, C., Pereira, J. P., Bates, E. E., Akira, S., Vieira, P., Liu, Y. J., Trinchieri, G. and O’Garra, A. 2006. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J. Immunol. 177:7551–7558.
   PubMed Web of Science ®Google Scholar
• Burris, J. M., Lundberg, J. K., Olsen, G. W., Simpson, C., and Mandel, J. H. 2002. Determination of Serum Half-lives of Several Fluorochemicals. Interim Report #2. St. Paul, MN:3M Company. U.S. EPA docket AR-226-1086. Washington, DC: U.S. Environmental Protection Agency.
   Google Scholar
• Butenhoff, J. L., Olsen, G. W. and Pfahles-Hutchens, A. 2006. The applicability of biomonitoring data for perfluorooctanesulfonate to the environmental public health continuum. Environ. Health Perspect. 114:1776–1782.
   PubMed Web of Science ®Google Scholar
• Calafat, A. M., Kuklenyik, Z., Reidy, J. A., Caudill, S. P., Tully, J. S. and Needham, L. L. 2007. Serum concentrations of 11 polyfluoroalkyl compounds in the u.s. population: Data from the national health and nutrition examination survey (NHANES). Environ. Sci. Technol. 41:2237–2242.
   PubMed Web of Science ®Google Scholar
• de Vos, M. G., Huijbregts, M. A., van den Heuvel-Greve, M. J., Vethaak, A. D., Van de Vijver, K. I., Leonards, P. E., van Leeuwen, S. P., de Voogt, P. and Hendriks, A. J. 2008. Accumulation of perfluorooctane sulfonate (PFOS) in the food chain of the Western Scheldt estuary: Comparing field measurements with kinetic modeling. Chemosphere 70:1766–1773.
   PubMed Web of Science ®Google Scholar
• Dewitt, J. C., Copeland, C. B., Strynar, M. J. and Luebke, R. W. 2008. Perfluorooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ. Health Perspect. 116:644–650.
   PubMed Web of Science ®Google Scholar
• Dong, G. H., Zhang, Y. H., Zheng, L., Liu, W., Jin, Y. H. and He, Q. C. 2009. Chronic effects of perfluorooctanesulfonate exposure on immunotoxicity in adult male C57BL/6 mice. Arch. Toxicol. 83:805–815.
   PubMed Web of Science ®Google Scholar
• Fietta, P. and Delsante, G. 2009. The effector T-helper cell triade. Riv. Biol. 102:61–74.
   Google Scholar
• Francis, J., MohanKumar, S. M. and MohanKumar, P. S. 2000. Correlations of norepinephrine release in the paraventricular nucleus with plasma corticosterone and leptin after systemic lipopolysaccharide: Blockade by soluble IL-1 receptor. Brain Res. 867:180–187.
   PubMed Web of Science ®Google Scholar
• Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoué, F., Bruneval, P., Cugnenc, P. H., Trajanoski, Z., Fridman, W. H. and Pagès, F. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964.
   PubMed Web of Science ®Google Scholar
• Giesy, J. P. and Kannan, K. 2001. Global distribution of perfluorooctane sulfonate in wildlife. Environ. Sci. Technol. 35:1339–1342.
   PubMed Web of Science ®Google Scholar
• Gilliland, F. D. and Mandel, J. S. 1993. Mortality among employees of a perfluorooctanoic acid production plant. J. Occup. Med. 35:950–954.
   PubMedGoogle Scholar
• Guruge, K. S., Hikono, H., Shimada, N., Murakami, K., Hasegawa, J., Yeung, L. W., Yamanaka, N. and Yamashita, N. 2009. Effect of perfluorooctane sulfonate (PFOS) on influenza A virus-induced mortality in female B6C3F1 mice. J. Toxicol. Sci. 34:687–691.
   PubMed Web of Science ®Google Scholar
• Hansen, K. J., Clemen, L. A., Ellefson, M. E. and Johnson, H. O. 2001. Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ. Sci. Technol. 35:766–770.
   PubMed Web of Science ®Google Scholar
• Hasbold, J., Hong, J. S., Kehry, M. R. and Hodgkin, P. D. 1999. Integrating signals from IFN-γ and IL-4 by B-cells: Positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a. J. Immunol. 163:4175–4181.
   Google Scholar
• Houde, M., Bujas, T. A., Small, J., Wells, R. S., Fair, P. A., Bossart, G. D., Solomon, K. R. and Muir, D. C. 2006. Biomagnification of perfluoroalkyl compounds in the bottlenose dolphin (Tursiops truncatus) food web. Environ. Sci. Technol. 40:4138–4144.
   PubMed Web of Science ®Google Scholar
• Jin, Y., Saito, N., Harada, K. H., Inoue, K. and Koizumi, A. 2007. Historical trends in human serum levels of perfluorooctanoate and perfluorooctane sulfonate in Shenyang, China. Tohoku J. Exp. Med. 212:63–70.
   PubMed Web of Science ®Google Scholar
• Kulmatycki, K. M. and Jamali, F. 2001. Therapeutic relevance of altered cytokine expression. Cytokine 14:1–10.
   PubMed Web of Science ®Google Scholar
• Lall, S. B. and Dan, G. 1999. Role of corticosteroids in cadmium induced immunotoxicity. Drug Chem. Toxicol. 22:401–409.
   PubMed Web of Science ®Google Scholar
• Lefebvre, D. E., Curran, I., Armstrong, C., Coady, L., Parenteau, M., Liston, V., Barker, M., Aziz, S., Rutherford, K., Bellon-Gagnon, P., Shenton, J., Mehta, R. and Bondy, G. 2008. Immunomodulatory effects of dietary potassium perfluorooctane sulfonate (PFOS) exposure in adult Sprague-Dawley rats. J. Toxicol. Environ. Health Part A 71:1516–1525.
   PubMed Web of Science ®Google Scholar
• Mosser, D. M. and Zhang, X. 2008. Interleukin-10: New perspectives on an old cytokine. Immunol. Rev. 226:205–218.
   PubMed Web of Science ®Google Scholar
• O’Garra, A. and Vieira, P. 2004. Regulatory T-cells and mechanisms of immune system control. Nat. Med. 10:801–805.
   PubMed Web of Science ®Google Scholar
• O’Garra, A. and Vieira, P. 2007. TH1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7:425–428.
   PubMed Web of Science ®Google Scholar
• OECD (Organization for Economic Co-operation and Development). 2002. Hazard Assessment of Perfluorooctane Sulfonate (PFOS) and Its Salts. Available at http://www.oecd.org/dataoecd/23/18/2382880.pdf.
   Google Scholar
• Peden-Adams, M. M., Keller, J. M., Eudaly, J. G., Berger, J., Gilkeson, G. S. and Keil, D. E. 2008. Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol. Sci. 104:144–154.
   PubMed Web of Science ®Google Scholar
• Pène, J., Rousset, F., Brière, F., Chrétien, I., Bonnefoy, J. Y., Spits, H., Yokota, T., Arai, N., Arai, K. and Banchereau, J. 1988. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc. Natl. Acad. Sci. USA 85:6880–6884.
   PubMed Web of Science ®Google Scholar
• Qazi, M. R., Bogdanska, J., Butenhoff, J. L., Nelson, B. D., DePierre, J. W. and Abedi-Valugerdi, M. 2009a. High-dose, short-term exposure of mice to perfluorooctanesulfonate (PFOS) or perfluorooctanoate (PFOA) affects the number of circulating neutrophils differently, but enhances the inflammatory responses of macrophages to lipopolysaccharide (LPS) in a similar fashion. Toxicology 262:207–214.
   PubMed Web of Science ®Google Scholar
• Qazi, M. R., Xia, Z., Bogdanska, J., Chang, S. C., Ehresman, D. J., Butenhoff, J. L., Nelson, B. D., DePierre, J. W. and Abedi-Valugerdi, M. 2009b. The atrophy and changes in the cellular compositions of the thymus and spleen observed in mice subjected to short-term exposure to perfluorooctanesulfonate are high-dose phenomena mediated in part by peroxisome proliferator-activated receptor-α (PPARα). Toxicology 260:68–76.
   PubMed Web of Science ®Google Scholar
• Reichlin, S. 2004. Neuroendocrinology of acute immunity. J. Endocrinol. Invest. 27:48–61.
   Google Scholar
• Sato, M., Goto, S., Kaneko, R., Ito, M., Sato, S. and Takeuchi, S. 1998. Impaired production of TH1 cytokines and increased frequency of TH2 subsets in PBMC from advanced cancer patients. Anticancer Res. 18:3951–3955.
   PubMed Web of Science ®Google Scholar
• Seacat, A. M., Thomford, P. J., Hansen, K. J., Clemen, L. A., Eldridge, S. R., Elcombe, C. R. and Butenhoff, J. L. 2003. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183:117–131.
   PubMed Web of Science ®Google Scholar
• Shakhar, G. and Blumenfeld, B. 2003. Glucocorticoid involvement in suppression of NK activity following surgery in rats. J. Neuroimmunol. 138:83–91.
   PubMed Web of Science ®Google Scholar
• Spiegelberg, H. L. 1990. The role of interleukin-4 in IgE and IgG subclass formation. Springer Semin. Immunopathol. 12:365–383.
   Google Scholar
• Spiegelberg, H. L., Falkoff, R. J., O’Connor, R. D. and Beck, L. 1991. Interleukin-2 inhibits the interleukin-4-induced human IgE and IgG4 secretion in vivo. Clin. Exp. Immunol. 84:400–405.
   Google Scholar
• Yang, Q., Abedi-Valugerdi, M., Xie, Y., Zhao, X. Y., Möller, G., Nelson, B. D. and DePierre, J. W. 2002a. Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol. 2:389–397.
   PubMed Web of Science ®Google Scholar
• Yang, Q., Xie, Y. and Depierre, J. W. 2000. Effects of peroxisome proliferators on the thymus and spleen of mice. Clin. Exp. Immunol. 122:219–226.
   PubMed Web of Science ®Google Scholar
• Yang, Q., Xie, Y., Alexson, S. E., Nelson, B. D. and DePierre, J. W. 2002b. Involvement of the peroxisome proliferator-activated receptor-α in the immunomodulation caused by peroxisome proliferators in mice. Biochem. Pharmacol. 63:1893–1900.
   PubMed Web of Science ®Google Scholar
• Yang, Q., Xie, Y., Eriksson, A. M., Nelson, B. D. and DePierre, J. W. 2001. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice. Biochem. Pharmacol. 62:1133–1140.
   PubMed Web of Science ®Google Scholar
• Zheng, L., Dong, G. H., Jin, Y. H. and He, Q. C. 2009. Immunotoxic changes associated with a 7-day oral exposure to perfluorooctanesulfonate (PFOS) in adult male C57BL/6 mice. Arch. Toxicol. 83:679–689.
   PubMed Web of Science ®Google Scholar